Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Publication Type:
Journal Article
Authors:
Eron, J.J.;
Young, B.;
Cooper, D.A.;
Youle, M.;
DeJesus, E.;
J. Andrade-Villanueva;
Workman, C.;
Zajdenverg, R.;
Fatkenheuer, G.;
Berger, D.S.;
Kumar, P.N.;
Rodgers, A.J.;
Shaughnessy, M.A.;
Walker, M.L.;
Barnard, R.J.;
Miller, M.D.;
DiNubile, M.J.;
Nguyen, B.Y.;
Leavitt, R.;
Xu, X.;
Sklar, P.;
SWITCHMRK 1 and 2 investigatorsSource:
Lancet, Volume 375, Issue 9712, p.396-407 (2010)
Keywords:
abnormalities,
Adult,
adverse effects,
Aged,
Anti-HIV Agents,
blood,
Cholesterol,
Cholesterol,LDL,
Comparative Study,
Double-Blind Method,
Drug Administration Schedule,
drug effects,
drug therapy,
Drug Therapy,Combination,
Female,
genetics,
HIV Infections,
Hiv-1,
Humans,
Laboratories,
lopinavir,
Male,
Medicine,
methods,
Middle Aged,
Multicenter Studies,
North Carolina,
Patients,
physiopathology,
Pyrimidinones,
Pyrrolidinones,
Research,
Research Support,
Reverse Transcriptase Inhibitors,
ritonavir,
Rna,
Rna,Viral,
Safety,
Serum,
Tablets,
therapeutic use,
therapy,
Treatment Outcome,
Triglycerides,
Viremia,
virology
